Harrow Health

Harrow Health

Yahoo Finance • 5 days ago

Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target

On August 10, Harrow Inc. (NASDAQ:HROW) walked investors through a first half that fell short and a back half that now has to make up the difference. Revenue for the first six months of 2026 came in around $115 million, lighter than manage... Full story

Yahoo Finance • 14 days ago

Harrow Q2 Earnings Call Highlights

Key Points Interested in Harrow, Inc.? Here are five stocks we like better. Q2 revenue rose 11% year over year to $70.7 million, driven by stronger demand for VEVYE, IHEEZO and specialty products. Harrow reiterated its full-year revenue g... Full story

Yahoo Finance • 29 days ago

Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026

NASHVILLE, Tenn., July 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the second quarter e... Full story

Yahoo Finance • 2 months ago

Harrow Announces Commercial Launch of BYOOVIZ® in the United States

NASHVILLE, Tenn., July 01, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the commercial launch of BYOOVIZ® (ranibizumab-nuna), an FDA-appro... Full story

Yahoo Finance • 2 months ago

Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow

In July 2025, Samsung Bioepis entered into partnership with Harrow for commercialization of two interchangeable ophthalmology biosimilars — BYOOVIZ® (ranibizumab-nuna) and OPUVIZ™ (aflibercept-yszy) — in the US BYOOVIZ was the first ophtha... Full story

Yahoo Finance • 2 months ago

GROW Small Cap Equity Fund Covered Its Position in Harrow (HROW) in Q1

Grow Funds, an investment Advisor, released its Q1 2026 investor letter for "GROW Small Cap Equity Long/Short Fund". A copy of the letter can be downloaded here. In Q1 2026, GROW Small Cap Equity Long/Short L.P (Fund) returned 4.18%, outpe... Full story

Yahoo Finance • 2 months ago

Is Harrow, Inc. (HROW) A Good Stock To Buy Now?

Is HROW a good stock to buy? We came across a bullish thesis on Harrow, Inc. on TopSecretStocks's Substack by Simon. In this article, we will summarize the bulls' thesis on HROW. Harrow, Inc.'s share was trading at $33.10 as of June 8th. H... Full story

Yahoo Finance • 3 months ago

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

VERKAZIA is now supported by a comprehensive commercial strategy focused on physician education, patient access, and affordability initiatives to ensure dependable supply and remove access barriersVERKAZIA is indicated for the treatment of... Full story

Yahoo Finance • 3 months ago

Why Harmonic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

Shares of Harmonic Inc(NASDAQ:HLIT) rose sharply in pre-market trading after the company reported better-than-expected first-quarter financial results and issued second-quarter guidance above estimates. Also, the company raised its FY26 EP... Full story

Yahoo Finance • 4 months ago

Harrow Announces the Issuance of J-Code for IOPIDINE® 1%

NASHVILLE, Tenn., April 16, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that IOPIDINE® 1% (apraclonidine hydrochloride ophthalmic solutio... Full story

Yahoo Finance • 4 months ago

FDA sets up AdCom meeting to decide on lifting restrictions on certain peptides

[FDA Headquarters] The U.S. Food and Drug Administration (FDA) on Wednesday convened a group of independent advisors to recommend whether to allow compounding pharmacies to manufacture certain peptides. The peptides facing review by the... Full story

Yahoo Finance • 5 months ago

Harrow prices $50M senior unsecured notes due 2030 at 8.625%

* Harrow (Nasdaq: HROW [https://seekingalpha.com/symbol/HROW]) on Tuesday said it priced a private offering of $50 million in senior unsecured notes due 2030, bearing interest at 8.625% per year. * The notes will be issued under the sa... Full story

Yahoo Finance • 5 months ago

A Major Investor Just Sold $7.8 Million in Harrow Stock -- Is This a Sell Signal?

Opaleye Management Inc, a 10% Owner of Harrow(NASDAQ:HROW), reported the indirect sale of 198,572 shares of common stock in multiple open-market transactions on March 3 and March 4, 2026, for a total value of approximately $7.8 million, ac... Full story

Yahoo Finance • 6 months ago

Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing

On February 17, 2026, Opaleye Management Inc. reported selling out its entire stake in Immunome(NASDAQ:IMNM), an estimated $37.30 million trade based on quarterly average pricing. What Happened According to its SEC filing dated February... Full story

Yahoo Finance • 6 months ago

Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing

Opaleye Management Inc. disclosed in a February 17, 2026, SEC filing that it sold 180,000 shares of Liquidia(NASDAQ:LQDA), an estimated $5.12 million trade based on quarterly average pricing. What Happened According to a SEC filing dated... Full story

Yahoo Finance • 6 months ago

Harrow outlines $350M–$365M 2026 revenue goal as sales force expansion and pipeline advances fuel momentum

Earnings Call Insights: Harrow, Inc. (HROW) Q4 2025 MANAGEMENT VIEW * CEO Mark Baum highlighted, “Harrow now owns one of the largest portfolios of prescription ophthalmic products in the United States market, and we have been the most... Full story

Yahoo Finance • 6 months ago

Harrow Q4 Earnings Call Highlights

Harrow logo Key Points Strong 2025 results and upbeat 2026 guide: Harrow reported Q4 revenue of $89.1M (+33% YoY) and full-year revenue of $272M (+36%), with adjusted EBITDA of $61.9M for the year; management guides 2026 revenue of $350M... Full story

Yahoo Finance • 6 months ago

Harrow (HROW) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, March 3, 2026 at 8 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Mark L. Baum President and Chief Financial Officer — Andrew R. Boll Chief Commercial Officer — Patrick Sullivan Chief S... Full story

Yahoo Finance • 6 months ago

Harrow To Launch Phase 3 Trial Of TRIESENCE In Cataract Surgery Patients

(RTTNews) - Harrow Inc. (HROW) announced that the U.S. FDA has cleared its Investigational New Drug (IND) application to support a Phase 3 clinical trial of TRIESENCE (preservative-free triamcinolone acetonide injectable suspension, 40 mg/... Full story

Yahoo Finance • 6 months ago

Harrow Q4 Net Income Slips Despite 33% Revenue Growth; Issues FY26 Guidance; Stock Down

(RTTNews) - Harrow, Inc. (HROW), an eyecare pharmaceutical company, reported fourth-quarter results with a slip in net income despite 33% higher revenue, hurt by operating and income tax expenses. In addition, the firm provided fresh guida... Full story